Watch PTCT. Know when insiders buy.
One email the day a filing lands. Free.
Work order
42
WATCH · insiders 25, shorts 58
Insiders, 90 days
−$3.6M
net selling · 0 buys, 9 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
2 / 15
tracked funds hold it
Calls on record
0
nobody we score has called it yet
MKT CAP $5.8BP/E —DIV YIELD —FCF YIELD -0.69%REV TTM $1B −42.8%NET INCOME −$38.4M −106.1%NET CASH $956.7M52W 56.95 – 89.55NEXT EARNINGS Nov 5SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $360.5M | +101.5% | — | $149M | $83.5M | — | 0.92 | $129.1M | $2.2M | $126.9M | Jul 30 |
| Q1 2026 · Mar 31 | $272.6M | −76.8% | — | $45M | −$2.8M | −100.3% | -0.03 | −$59M | $1.2M | −$60.2M | May 7 |
| Q4 2025 · Dec 31derived | $164.7M | −22.7% | — | −$71.3M | −$135M | — | -1.67 | −$34.3M | $2.4M | −$36.6M | Feb 19 |
| Q3 2025 · Sep 30 | $211M | +7.2% | — | $3M | $15.9M | — | 0.20 | −$66.3M | $3.5M | −$69.8M | Nov 4 |
| Q2 2025 · Jun 30 | $178.9M | −4.2% | — | −$35M | −$64.8M | — | -0.83 | −$58.3M | $1.2M | −$59.6M | Jul 30 |
| Q1 2025 · Mar 31 | $1.2B | +459.7% | — | $970.2M | $866.6M | — | 10.04 | $870.1M | $1.7M | $868.4M | May 7 |
| Q4 2024 · Dec 31derived | $213.2M | −30.6% | — | −$162.4M | −$65.9M | — | -0.85 | −$30M | $3.8M | −$33.8M | Feb 19 |
| Q3 2024 · Sep 30 | $196.8M | +0.1% | — | −$54.5M | −$106.7M | — | -1.39 | −$77M | $522K | −$77.5M | Nov 4 |
| Q2 2024 · Jun 30 | $186.7M | — | — | −$40.2M | −$99.2M | — | -1.29 | −$71.5M | −$7.4M | −$64.1M | Aug 7 |
| Q1 2024 · Mar 31 | $210.1M | — | — | −$45.5M | −$91.6M | — | -1.20 | $70.8M | $9.6M | $61.2M | May 6 |
| Q4 2023 · Dec 31derived | $307.1M | — | — | $5.8M | −$155.8M | — | -2.06 | −$100.3M | $5.6M | −$105.9M | Feb 19 |
| Q3 2023 · Sep 30 | $196.6M | — | — | −$118.2M | −$133M | — | -1.76 | −$14.5M | $6.4M | −$20.9M | Nov 7 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $1.7B | — | $866.9M | $682.6M | 39.4% | 7.78 | $711.2M | $8.9M | $702.3M | — | — |
| FY2024 · to Dec 31 | $806.8M | — | −$302.6M | −$363.3M | -45.0% | -4.73 | −$107.7M | $6.5M | −$114.2M | — | — |
| FY2023 · to Dec 31 | $937.8M | — | −$439.5M | −$626.6M | -66.8% | -8.37 | −$158.4M | $28.4M | −$186.9M | — | — |
| FY2022 · to Dec 31 | $698.8M | — | −$447.4M | −$559M | -80.0% | -7.79 | −$356.7M | $32M | −$388.7M | — | — |
| FY2021 · to Dec 31 | $538.6M | — | −$374.4M | −$523.9M | -97.3% | -7.43 | −$251.3M | $28.2M | −$279.5M | — | — |
| FY2020 · to Dec 31 | $380.8M | — | −$431.8M | −$438.2M | -115.1% | -6.64 | −$194.1M | $17.8M | −$211.9M | — | — |
Every number comes from PTC THERAPEUTICS, INC.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.